JP2022527473A - アンチセンスを用いてがんを治療するための方法 - Google Patents

アンチセンスを用いてがんを治療するための方法 Download PDF

Info

Publication number
JP2022527473A
JP2022527473A JP2021557634A JP2021557634A JP2022527473A JP 2022527473 A JP2022527473 A JP 2022527473A JP 2021557634 A JP2021557634 A JP 2021557634A JP 2021557634 A JP2021557634 A JP 2021557634A JP 2022527473 A JP2022527473 A JP 2022527473A
Authority
JP
Japan
Prior art keywords
subject
igf
odn
chamber
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557634A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020198587A5 (https=
JP2022527473A5 (https=
Inventor
シー． フーパー、ダグラス
ダブリュ． アンドリューズ、デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of JP2022527473A publication Critical patent/JP2022527473A/ja
Publication of JPWO2020198587A5 publication Critical patent/JPWO2020198587A5/ja
Publication of JP2022527473A5 publication Critical patent/JP2022527473A5/ja
Priority to JP2025031086A priority Critical patent/JP2025098027A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2021557634A 2019-03-28 2020-03-27 アンチセンスを用いてがんを治療するための方法 Pending JP2022527473A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025031086A JP2025098027A (ja) 2019-03-28 2025-02-28 アンチセンスを用いてがんを治療するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825516P 2019-03-28 2019-03-28
US62/825,516 2019-03-28
PCT/US2020/025217 WO2020198587A1 (en) 2019-03-28 2020-03-27 Methods for treating cancers using antisense

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025031086A Division JP2025098027A (ja) 2019-03-28 2025-02-28 アンチセンスを用いてがんを治療するための方法

Publications (3)

Publication Number Publication Date
JP2022527473A true JP2022527473A (ja) 2022-06-02
JPWO2020198587A5 JPWO2020198587A5 (https=) 2023-04-04
JP2022527473A5 JP2022527473A5 (https=) 2023-04-04

Family

ID=72609134

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557634A Pending JP2022527473A (ja) 2019-03-28 2020-03-27 アンチセンスを用いてがんを治療するための方法
JP2025031086A Pending JP2025098027A (ja) 2019-03-28 2025-02-28 アンチセンスを用いてがんを治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025031086A Pending JP2025098027A (ja) 2019-03-28 2025-02-28 アンチセンスを用いてがんを治療するための方法

Country Status (7)

Country Link
US (1) US20220195440A1 (https=)
EP (1) EP3946287A4 (https=)
JP (2) JP2022527473A (https=)
AU (1) AU2020244865A1 (https=)
CA (1) CA3134969A1 (https=)
MX (1) MX2021011760A (https=)
WO (1) WO2020198587A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108291227A (zh) 2015-10-14 2018-07-17 拜奥-帕斯控股股份有限公司 用于脂质体制剂的对乙氧基核酸
AU2017325971A1 (en) 2016-09-16 2019-04-11 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
EA201992485A1 (ru) 2017-04-19 2020-02-17 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования stat3
EA201992490A1 (ru) 2017-04-19 2020-03-03 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования bcl2
WO2024077130A1 (en) * 2022-10-05 2024-04-11 Thomas Jefferson University Methods and compositions for treating bladder cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165528A1 (en) * 2017-03-09 2018-09-13 Thomas Jefferson University Methods and compositions for treating cancers using antisense

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541036B1 (en) * 1997-05-29 2003-04-01 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
WO2002027019A1 (en) * 2000-09-29 2002-04-04 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
NZ554831A (en) * 2004-11-09 2009-10-30 Schering Corp Improved dosing regimen of temozolomide for treating cancer based on the patientÆs MGMT level
EP1900825A1 (en) * 2006-09-13 2008-03-19 Rheinische Friedrich-Wilhelms-Universität Bonn Sensitive and reproducible method for the determination of MGMT promoter methylation in clinical samples
CA2783665A1 (en) * 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2016164916A1 (en) * 2015-04-10 2016-10-13 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165528A1 (en) * 2017-03-09 2018-09-13 Thomas Jefferson University Methods and compositions for treating cancers using antisense

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JNH JOURNAL, vol. Vol. 13, Issue 1, Art. 2, JPN7024000895, 2018, pages 7 - 13, ISSN: 0005275677 *
ONCOTARGET, vol. 6, no. 37, JPN7024000894, 2015, pages 39877 - 39890, ISSN: 0005275676 *

Also Published As

Publication number Publication date
AU2020244865A1 (en) 2021-10-21
US20220195440A1 (en) 2022-06-23
CA3134969A1 (en) 2020-10-01
EP3946287A1 (en) 2022-02-09
WO2020198587A1 (en) 2020-10-01
JP2025098027A (ja) 2025-07-01
MX2021011760A (es) 2021-12-10
EP3946287A4 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
JP7656350B2 (ja) アンチセンスを用いて癌を治療するための方法及び組成物
JP2022527473A (ja) アンチセンスを用いてがんを治療するための方法
JP2024163121A (ja) アンチセンスを使用した肝細胞癌治療用の方法および組成物
JP2025010156A (ja) アンチセンスを使用した乳癌治療用の方法および組成物
HK40112216A (en) Methods and compositions for treating cancers using antisense
HK40022361A (en) Compositions for treating cancers using antisense
HK40022361B (en) Compositions for treating cancers using antisense
BR122025011178A2 (pt) Métodos e composições para tratamento de cânceres utilizando antissenso

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228